These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 30645203)

  • 1. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.
    Furie R; Werth VP; Merola JF; Stevenson L; Reynolds TL; Naik H; Wang W; Christmann R; Gardet A; Pellerin A; Hamann S; Auluck P; Barbey C; Gulati P; Rabah D; Franchimont N
    J Clin Invest; 2019 Mar; 129(3):1359-1371. PubMed ID: 30645203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus.
    Hartmann S; Biliouris K; Naik H; Rabah D; Stevenson L; Shen C; Nestorov IA; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):255-266. PubMed ID: 32335844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.
    Pellerin A; Otero K; Czerkowicz JM; Kerns HM; Shapiro RI; Ranger AM; Otipoby KL; Taylor FR; Cameron TO; Viney JL; Rabah D
    EMBO Mol Med; 2015 Apr; 7(4):464-76. PubMed ID: 25762615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.
    Biliouris K; Nestorov I; Naik H; Dai D; Xiao G; Wang Q; Pellerin A; Rabah D; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):817-827. PubMed ID: 30377889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of
    Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
    Front Immunol; 2019; 10():275. PubMed ID: 30846987
    [No Abstract]   [Full Text] [Related]  

  • 6. Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
    Werth VP; Furie RA; Romero-Diaz J; Navarra S; Kalunian K; van Vollenhoven RF; Nyberg F; Kaffenberger BH; Sheikh SZ; Radunovic G; Huang X; Clark G; Carroll H; Naik H; Gaudreault F; Meyers A; Barbey C; Musselli C; Franchimont N;
    N Engl J Med; 2022 Jul; 387(4):321-331. PubMed ID: 35939578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
    Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
    Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
    Furie RA; van Vollenhoven RF; Kalunian K; Navarra S; Romero-Diaz J; Werth VP; Huang X; Clark G; Carroll H; Meyers A; Musselli C; Barbey C; Franchimont N;
    N Engl J Med; 2022 Sep; 387(10):894-904. PubMed ID: 36069871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A promising approach to targeting type 1 IFN in systemic lupus erythematosus.
    Chaichian Y; Wallace DJ; Weisman MH
    J Clin Invest; 2019 Mar; 129(3):958-961. PubMed ID: 30776023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus.
    Cho YM; Furie R
    Immunotherapy; 2024 Jan; 16(1):15-20. PubMed ID: 37877249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased plasmacytoid dendritic cells and RORγt-expressing immune effectors in cutaneous acute graft-versus-host disease.
    Malard F; Bossard C; Brissot E; Chevallier P; Guillaume T; Delaunay J; Mosnier JF; Moreau P; Grégoire M; Gaugler B; Mohty M
    J Leukoc Biol; 2013 Dec; 94(6):1337-43. PubMed ID: 23990625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus.
    Blomberg S; Eloranta ML; Magnusson M; Alm GV; Rönnblom L
    Arthritis Rheum; 2003 Sep; 48(9):2524-32. PubMed ID: 13130472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H; Li T; Chen S; Gu Y; Ye S
    Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma.
    Ross RL; Corinaldesi C; Migneco G; Carr IM; Antanaviciute A; Wasson CW; Carriero A; Distler JHW; Holmes S; El-Sherbiny YM; McKimmie CS; Del Galdo F
    Ann Rheum Dis; 2021 Jul; 80(7):920-929. PubMed ID: 33542104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus.
    Cho SK; Vazquez T; Werth VP
    Expert Opin Investig Drugs; 2023 May; 32(5):345-353. PubMed ID: 37148249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunomodulatory antibody-drug conjugate targeting BDCA2 strongly suppresses plasmacytoid dendritic cell function and glucocorticoid responsive genes.
    Li X; Zhang Y; Li B; Li J; Qiu Y; Zhu Z; Hua H
    Rheumatology (Oxford); 2024 Jan; 63(1):242-250. PubMed ID: 37184875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus.
    Shi ZR; Tan GZ; Meng Z; Yu M; Li KW; Yin J; Wei KH; Luo YJ; Jia SQ; Zhang SJ; Wu J; Mi XB; Wang L
    Arthritis Rheumatol; 2015 Jan; 67(1):193-203. PubMed ID: 25307291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.
    Hasni S; Gupta S; Davis M; Poncio E; Temesgen-Oyelakin Y; Joyal E; Fike A; Manna Z; Auh S; Shi Y; Chan D; Carlucci P; Biehl A; Dema B; Charles N; Balow JE; Waldman M; Siegel RM; Kaplan MJ; Rivera J
    Arthritis Rheumatol; 2019 Jul; 71(7):1135-1140. PubMed ID: 30597768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.